Evidence map›Paper›PMID 40392313›Full record

ReviewMolecular genetics and genomics : MGG2025

HES1 in cancer: a key player in tumorigenesis and its prognostic significance.

Venkataraman Magesh, Ramya Sekar, Abdullah AlZahrani, Rajkapoor Balasubramanian, Salaheldin Abdelraouf Abdelsalam, Peramaiyan Rajendran

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular genetics and genomics : MGG, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Venkataraman MageshAcubiosys Pvt Ltd, TSSIC-IALA, Hyderabad, 500040, India.
Ramya SekarDepartment of Oral & Maxillofacial Pathology and Oral Microbiology, Meenakshi Ammal Dental College and Hospital, Meenakshi Academy of Higher Education and Research (Deemed to Be University), Chennai, Tamil Nadu, India.ORCID http://orcid.org/0000-0003-0381-2859
Abdullah AlZahraniDepartment of Biological Sciences, College of Science, King Faisal University, Al-Ahsa, Saudi Arabia.
Rajkapoor BalasubramanianDepartment of Pharmacology, J.K.K Nataraja College of Pharmacy, Komarapalayam, Tamil Nadu, India.
Salaheldin Abdelraouf AbdelsalamDepartment of Biological Sciences, College of Science, King Faisal University, Al-Ahsa, Saudi Arabia.
Peramaiyan RajendranDepartment of Biological Sciences, College of Science, King Faisal University, Al-Ahsa, Saudi Arabia. prajendran@kfu.edu.sa.

Funding

Deanship of Scientific Research, King Faisal University Grant No. 1254
6 · The paper itself

Abstract

The dysregulation of transcriptional regulators is a critical feature in the progression of many malignancies. Hairy and enhancer of split homolog-1 (HES1), a member of the basic helix-loop-helix (bHLH) gene family, has emerged as a key player in tumorigenesis due to its regulatory roles in multiple cellular pathways. This review aims to systematically explore the relevance of HES1 in cancer development, emphasizing its activation through major signaling pathways such as Notch, Hedgehog, hypoxia, and Wnt, and its contribution to advanced tumor progression. Numerous studies have demonstrated that HES1 upregulates genes associated with stemness, proliferation, and metastasis, and its expression correlates with poor clinicopathological features, including enhanced tumor proliferation, self-renewal, migration, metastasis, and drug resistance. Furthermore, HES1 has been frequently identified as a downstream effector of critical oncogenic pathways, further consolidating its role in aggressive cancers. Based on current evidence, HES1 holds promise as both a prognostic biomarker and a potential therapeutic target in various lethal malignancies. A deeper understanding of HES1's molecular mechanisms could pave the way for the development of targeted interventions aimed at improving cancer outcomes.

Indexed as

CarcinogenesisNeoplasmsTranscription Factor HES-1AnimalsBiomarkers, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansPrognosisSignal TransductionBiomarkers, TumorHES1 protein, humanTranscription Factor HES-1BiomarkerCancerHES1NotchTherapeutic target

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.